Sirolimus for refractory vascular anomalies

Pediatric Blood and Cancer

Volumn 57, Issue 6, 2011, Pages 904-905

  Trenor, Cameron C ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; OCTREOTIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROPRANOLOL; RAPAMYCIN;

ANGIOGENESIS; ANTICOAGULATION; ARTIFICIAL EMBOLISM; BLOOD CLOTTING DISORDER; BRADYCARDIA; CAPILLARY HEMANGIOMA; CONGENITAL BLOOD VESSEL MALFORMATION; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GENE MUTATION; HEMANGIOENDOTHELIOMA; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOTENSION; KAPOSIFORM HEMANGIOENDOTHELIOMA; KASABACH MERRITT SYNDROME; LYMPHATIC SYSTEM DISEASE; MYOFASCIAL PAIN; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PLEURODESIS; PRIORITY JOURNAL; REFRACTORY VASCULAR ANOMALY; SCLEROTHERAPY; SEIZURE; THORACIC DUCT; TREATMENT RESPONSE; VASCULAR TUMOR;

FEMALE; HUMANS; MALE; SIROLIMUS; VASCULAR MALFORMATIONS;

EID: 80052682015     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23178     Document Type: Note

References (16)

1. Adams DM, Wentzel MS. The role of the hematologist/oncologist in the care of patients with vascular anomalies. Pediatr Clin North Am 2008;55:339-355 viii.
2. Blatt J, Stavas J, Moats-Staats B, Woosley J, Morrell DS. Treatment of childhood Kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer 2010;55:1396-1398.
3. Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions after Kasabach-Merritt phenomenon in 41 patients. J Am Acad Dermatol 2000;42:225-235.
4. Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE. Thrombocytopenic coagulopathy (Kasabach-Merritt phenomenon) is associated with Kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997;100:1377-1386.
5. Marsh DJ, Trahair TN, Martin JL, et al. Rapamycin treatment for a child with germline PTEN mutation. Nat Clin Pract Oncol 2008;5:357-361.
6. Iacobas I, Burrows PE, Adams DM, Sutton VR, Hollier LH, Chintagumpala MM. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer 2011. DOI: 10.1002/pbc.23098. [Epub ahead of print].
7. Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008;358:140-151.
8. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358:2649-2651.
9. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: Risks and recommendations. Pediatr Dermatol 2009;26:610-614.
10. Breur JM, de Graaf M, Breugem CC, Pasmans SG. Hypoglycemia as a result of propranolol during treatment of infantile hemangioma: A case report. Pediatr Dermatol 2010. [Epub ahead of print].
11. Holland KE, Frieden IJ, Frommelt PC, Mancini AJ, Wyatt D, Drolet BA. Hypoglycemia in children taking propranolol for the treatment of infantile hemangioma. Arch Dermatol 2010;146:775-778.
12. Bonifazi E, Acquafredda A, Milano A, Montagna O, Laforgia N. Severe hypoglycemia during successful treatment of diffuse hemangiomatosis with propranolol. Pediatr Dermatol 2010;27:195-196.
13. Pavlakovic H, Kietz S, Lauerer P, Zutt M, Lakomek M. Hyperkalemia complicating propranolol treatment of an infantile hemangioma. Pediatrics 2010;126:e1589-93.
14. Abbott J, Parulekar M, Shahidullah H, Taibjee S, Moss C. Diarrhea associated with propranolol treatment for hemangioma of infancy (HOI). Pediatr Dermatol 2010;27:558.
15. Fusilli G, Merico G, Gurrado R, Rosa T, Acquafredda A, Cavallo L. Propranolol for infantile haemangiomas and neuroglycopenic seizures. Acta Paediatr 2010;99:1756.
16. Alvarez-Garcia O, Garcia-Lopez E, Loredo V, et al. Rapamycin induces growth retardation by disrupting angiogenesis in the growth plate. Kidney Int 2010;78:561-568.